NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance

详细信息    查看全文

• 作者：David C. Austin ; Douglas W. Strand ; Harold L. Love ; Omar E. Franco ; Magdalena M. Grabowska ; Nicole L. Miller ; Omar Hameed ; Peter E. Clark ; Robert J. Matusik ; Ren J. Jin and Simon W. Hayward
• 刊名：The Prostate
• 出版年：2016
• 出版时间：August 1, 2016
• 年：2016
• 卷：76
• 期：11
• 页码：1004-1018
• 全文大小：3583K
• ISSN：1097-0045

文摘

Benign prostatic hyperplasia (BPH) is treated with 5α-reductase inhibitors (5ARI). These drugs inhibit the conversion of testosterone to dihydrotestosterone resulting in apoptosis and prostate shrinkage. Most patients initially respond to 5ARIs; however, failure is common especially in inflamed prostates, and often results in surgery. This communication examines a link between activation of NF-κB and increased expression of SRD5A2 as a potential mechanism by which patients fail 5ARI therapy.